From: Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma
Conventional Group (n = 32)
NACT (n = 18)
Optimum cytoreduction
20(62.5%)
13(72.2%)
Suboptimal cytoreduction
12(37.5%0
5(27.8%)